{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:13Z","timestamp":1792794733329,"version":"4.5.0"},"reference-count":111,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Neurodegenerative disorders (NDs) have become a serious health problem worldwide due to the rapid increase in the number of people that are affected and the constantly aging population. Among all NDs, Alzheimer\u2019s and Parkinson\u2019s disease are the most common, and many efforts have been made in the development of effective and reliable therapeutic strategies. The intranasal route of drug administration offers numerous advantages, such as bypassing the blood\u2013brain barrier and providing a direct entrance to the brain through the olfactory and trigeminal neurons. The present review summarizes the available information on recent advances in micro- and nanoscale nose-to-brain drug-delivery systems as a novel strategy for the treatment of Alzheimer\u2019s and Parkinson\u2019s disease. Specifically, polymer- and lipid-base micro- and nanoparticles have been studied as a feasible approach to increase the brain bioavailability of certain drugs. Furthermore, nanocomposites are discussed as a suitable formulation for administration into the nasal cavity.<\/jats:p>","DOI":"10.3390\/biomedicines10071706","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:17:10Z","timestamp":1657844230000},"page":"1706","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery in Neurodegenerative Disorders"],"prefix":"10.3390","volume":"10","author":[{"given":"Radka","family":"Boyuklieva","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5737-536X","authenticated-orcid":false,"given":"Bissera","family":"Pilicheva","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"},{"name":"Research Institute at Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020\u20132060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"Olesen","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.37765\/ajmc.2020.88482","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26","author":"Wong","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Teleanu, D.M., Niculescu, A.-G., Lungu, I.I., Radu, C.I., Vlad\u00e2cenco, O., Roza, E., Cost\u0103chescu, B., Grumezescu, A.M., and Teleanu, R.I. (2022). An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23115938"},{"key":"ref_5","unstructured":"Stoker, T.B., and Greenland, J.C. (2018). Parkinson\u2019s disease: Etiology, neuropathology, and pathogenesis. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Chapter 13-Alzheimer\u2019s disease","volume":"Volume 167","author":"Dekosky","year":"2019","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1537","article-title":"Iron, brain ageing and neurodegenerative disorders","volume":"5","author":"Zecca","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"618360","DOI":"10.3389\/fnmol.2021.618360","article-title":"Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I","volume":"14","author":"Belur","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jconrel.2014.06.017","article-title":"Agile delivery of protein therapeutics to CNS","volume":"190","author":"Yi","year":"2014","journal-title":"J. Control Release"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","article-title":"Anatomical and histological factors affecting intranasal drug and vaccine delivery","volume":"9","author":"Gizurarson","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"G\u00e4nger, S., and Schindowski, K. (2018). Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030116"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1089\/jamp.2019.1549","article-title":"Olfactory Targeting of Microparticles Through Inhalation and Bi-directional Airflow: Effect of Particle Size and Nasal Anatomy","volume":"33","author":"Yarragudi","year":"2020","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Bors","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Crowe, T.P., and Hsu, W.H. (2022). Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030629"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0928-0987(01)00151-8","article-title":"Levels of dopamine in blood and brain following nasal administration to rats","volume":"14","author":"Dahlin","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: A transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"120474","DOI":"10.1016\/j.ijpharm.2021.120474","article-title":"Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies","volume":"600","author":"Patel","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jps.20480","article-title":"Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting","volume":"95","author":"Vyas","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1208\/pt070108","article-title":"Preliminary Brain-targeting Studies on Intranasal Mucoadhesive Microemulsions of Sumatriptan","volume":"7","author":"Vyas","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/1061186X.2011.558090","article-title":"Nose-to-brain transport of melatonin from polymer gel suspensions: A microdialysis study in rats","volume":"19","author":"Dayal","year":"2011","journal-title":"J. Drug Target"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Maiti, S.K., and Sen, K.K. (2017). Introductory Chapter: Drug Delivery Concepts. Advanced Technology for Delivering Therapeutics, IntechOpen.","DOI":"10.5772\/65245"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jddst.2015.05.002","article-title":"Particulate formulations based on chitosan for nose-to-brain delivery of drugs","volume":"32","author":"Rassu","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1002\/jps.21335","article-title":"Brain uptake of an anti-ischemic agent by nasal administration of microparticles","volume":"97","author":"Dalpiaz","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jddst.2016.05.003","article-title":"Formulation and device design to increase nose to brain drug delivery","volume":"35","author":"Warnken","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1359-0294(00)00046-7","article-title":"Physicochemical aspects of drug delivery and release from polymer-based colloids","volume":"5","author":"Yang","year":"2000","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lengyel, M., K\u00e1llai-Szab\u00f3, N., Antal, V., Laki, A.J., and Antal, I. (2019). Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery. Sci. Pharm., 87.","DOI":"10.3390\/scipharm87030020"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/3-540-32702-9_3","article-title":"Microparticles Used as Drug Delivery Systems","volume":"Volume 133","author":"Richtering","year":"2006","journal-title":"Smart Colloidal Materials"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s13167-010-0001-x","article-title":"Drug delivery systems: Advanced technologies potentially applicable in personalized treatments","volume":"1","author":"Coelho","year":"2010","journal-title":"EPMA J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Maaz, A., Blagbrough, I.S., and De Bank, P.A. (2021). In Vitro Evaluation of Nasal Aerosol Depositions: An Insight for Direct Nose to Brain Drug Delivery. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071079"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1208\/s12249-014-0092-0","article-title":"Mechanisms of pharmaceutical aerosol deposition in the respiratory tract","volume":"15","author":"Cheng","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/10611860802556842","article-title":"Mucoadhesive microspheres for nasal administration of cyclodextrins","volume":"17","author":"Gavini","year":"2009","journal-title":"J. Drug Target"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Onukwufor, J.O., Dirksen, R.T., and Wojtovich, A.P. (2022). Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer\u2019s Disease. Antioxidants, 11.","DOI":"10.3390\/antiox11040692"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Peng, Y., Chang, X., and Lang, M. (2021). Iron Homeostasis Disorder and Alzheimer\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212442"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Reinert, A., Morawski, M., Seeger, J., Arendt, T., and Reinert, T. (2019). Iron concentrations in neurons and glial cells with estimates on ferritin concentrations. BMC Neurosci., 20.","DOI":"10.1186\/s12868-019-0507-7"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnins.2019.00180","article-title":"Iron in Neurodegeneration\u2013Cause or Consequence?","volume":"13","author":"Ndayisaba","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Rockfield, S., Chhabra, R., Robertson, M., Rehman, N., Bisht, R., and Nanjundan, M. (2018). Links Between Iron and Lipids: Implications in Some Major Human Diseases. Pharmaceuticals, 11.","DOI":"10.3390\/ph11040113"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nu\u00f1ez, M.T., and Chana-Cuevas, P. (2018). New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases. Pharmaceuticals, 11.","DOI":"10.3390\/ph11040109"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tips.2017.02.005","article-title":"Ferroptosis inhibition: Mechanisms and opportunities","volume":"38","author":"Angeli","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kosyakovsky, J., Fine, J.M., Frey, W.H., and Hanson, L.R. (2021). Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020095"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2015.01.025","article-title":"Solid microparticles based on chitosan or methyl-\u03b2-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate","volume":"201","author":"Rassu","year":"2015","journal-title":"J. Control Release"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/10837450.2019.1567762","article-title":"Spray-dried alginate microparticles for potential intranasal delivery of ropinirole hydrochloride: Development, characterization and histopathological evaluation","volume":"25","author":"Hussein","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1586\/14737175.4.4.581","article-title":"Ropinirole therapy for Parkinson\u2019s disease","volume":"4","author":"Pahwa","year":"2004","journal-title":"Expert Rev. Neurother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.22159\/ajpcr.2017.v10i7.18475","article-title":"Formulation design and characterization of ropinirole hydrochoride microsphere for intranasal delivery","volume":"10","author":"Mantry","year":"2017","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Batiha, G.E.-S., Beshbishy, A.M., Ikram, M., Mulla, Z.S., El-Hack, M.E.A., Taha, A.E., Algammal, A.M., and Elewa, Y.H.A. (2020). The Pharmacological Activity, Biochemical Properties, and Pharmacokinetics of the Major Natural Polyphenolic Flavonoid: Quercetin. Foods, 9.","DOI":"10.3390\/foods9030374"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1021\/acs.molpharmaceut.0c00672","article-title":"Preparation and biophysical characterization of inclusion complexes with \u03b2-cyclodextrin derivatives for the preparation of possible nose-to-brain Quercetin delivery systems","volume":"17","author":"Manta","year":"2020","journal-title":"Mol. Pharmaceut."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"121016","DOI":"10.1016\/j.ijpharm.2021.121016","article-title":"Nasal powders of quercetin-\u03b2-cyclodextrin derivatives complexes with mannitol\/lecithin microparticles for Nose-to-Brain delivery: In vitro and ex vivo evaluation","volume":"607","author":"Papakyriakopoulou","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"111829","DOI":"10.1016\/j.biopha.2021.111829","article-title":"Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer\u2019s disease","volume":"141","author":"Gao","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2042098617750555","article-title":"An update on the safety of current therapies for Alzheimer\u2019s disease: Focus on rivastigmine","volume":"9","author":"Khoury","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.carbpol.2017.01.044","article-title":"Formulation of olfactory-targeted microparticles with tamarind seed polysaccharide to improve the transport of drugs","volume":"163","author":"Yarragudi","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Chawananorasest, K., Saengtongdee, P., and Kaemchantuek, P. (2016). Extraction and Characterization of Tamarind (Tamarind indica L.) Seed Polysaccharides (TSP) from Three Difference Sources. Molecules, 21.","DOI":"10.3390\/molecules21060775"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Salehi, B., Mishra, A.P., Nigam, M., Sener, B., Kilic, M., Sharifi-Rad, M., Fokou, P.V.T., Martins, N., and Sharifi-Rad, J. (2018). Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines, 6.","DOI":"10.3390\/biomedicines6030091"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kou, X., and Chen, N. (2017). Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer\u2019s Disease. Nutrients, 9.","DOI":"10.3390\/nu9090927"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kung, H.-C., Lin, K.-J., Kung, C.-T., and Lin, T.-K. (2021). Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson\u2019s Disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080918"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/neurosci2030022","article-title":"Neuroprotective Effects of Resveratrol in Ischemic Brain Injury","volume":"2","author":"Machado","year":"2021","journal-title":"NeuroSci"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Faggi, L., Pignataro, G., Parrella, E., Porrini, V., Vinciguerra, A., Cepparulo, P., Cuomo, O., Lanzillotta, A., Mota, M., and Benarese, M. (2018). Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010172"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Chuang, Y.-C., Chen, S.-D., Hsu, C.-Y., Chen, S.-F., Chen, N.-C., and Jou, S.-B. (2019). Resveratrol Promotes Mitochondrial Biogenesis and Protects against Seizure-Induced Neuronal Cell Damage in the Hippocampus Following Status Epilepticus by Activation of the PGC-1\u03b1 Signaling Pathway. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040998"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zamora-Bello, I., Rivadeneyra-Dom\u00ednguez, E., and Rodr\u00edguez-Landa, J.F. (2022). Anticonvulsant Effect of Turmeric and Resveratrol in Lithium\/Pilocarpine-Induced Status Epilepticus in Wistar Rats. Molecules, 27.","DOI":"10.3390\/molecules27123835"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"837042","DOI":"10.1155\/2015\/837042","article-title":"Properties of resveratrol: In vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans","volume":"2015","author":"Gambini","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Garza, S.L., Laveriano-Santos, E.P., Marhuenda-Mu\u00f1oz, M., Storniolo, C.E., Tresserra-Rimbau, A., Vallverd\u00fa-Queralt, A., and Lamuela-Ravent\u00f3s, R.M. (2018). Health Effects of Resveratrol: Results from Human Intervention Trials. Nutrients, 10.","DOI":"10.3390\/nu10121892"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejpb.2018.02.010","article-title":"Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles","volume":"127","author":"Trotta","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.2174\/0929867321666140716103130","article-title":"Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders","volume":"21","author":"Ong","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J. Control Release."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"601626","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neulet.2008.12.056","article-title":"Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes","volume":"451","author":"Lim","year":"2009","journal-title":"Neurosci. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/syn.10248","article-title":"Pharmacokinetic and pharmacodynamic analyses, based on dopamine D2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats","volume":"50","author":"Atsumi","year":"2003","journal-title":"Synapse"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","article-title":"Bromocriptine-loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mouse model","volume":"48","author":"Md","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3109\/03639045.2014.991400","article-title":"Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting","volume":"41","author":"Jafarieh","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","article-title":"Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting","volume":"47","author":"Fazil","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: A review of its use in Alzheimer\u2019s disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Nanaki, S.G., Spyrou, K., Bekiari, C., Veneti, P., Baroud, T.N., Karouta, N., Grivas, I., Papadopoulos, G.C., Gournis, D., and Bikiaris, D.N. (2020). Hierarchical Porous Carbon\u2014PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer\u2019s Disease Therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030227"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Friedli, M., and Inestrosa, N.C. (2021). Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer\u2019s Disease. Molecules, 26.","DOI":"10.3390\/molecules26216531"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/cbdv.201000269","article-title":"Huperzine a as potential treatment of Alzheimer\u2019s disease: An assessment on chemistry, pharmacology, and clinical studies","volume":"8","author":"Ha","year":"2011","journal-title":"Chem. Biodivers."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Rassu, G., Porcu, E.P., Fancello, S., Obinu, A., Senes, N., Galleri, G., Migheli, R., Gavini, E., and Giunchedi, P. (2019). Intranasal delivery of genistein-loaded nanoparticles as a potential preventive system against neurodegenerative disorders. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11010008"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Park, Y.-J., Ko, J.W., Jeon, S., and Kwon, Y.H. (2016). Protective Effect of Genistein against Neuronal Degeneration in ApoE\u2212\/\u2212 Mice Fed a High-Fat Diet. Nutrients, 8.","DOI":"10.3390\/nu8110692"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/IJN.S247935","article-title":"Primary Studies on Construction and Evaluation of Ion-Sensitive in situ Gel Loaded with Paeonol-Solid Lipid Nanoparticles for Intranasal Drug Delivery","volume":"15","author":"Sun","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","article-title":"Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer\u2019s therapy","volume":"152","author":"Rassu","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cortex.2008.11.010","article-title":"Parkinson\u2019s disease: The syndrome, the pathogenesis and pathophysiology","volume":"45","author":"Bartels","year":"2009","journal-title":"Cortex"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/mds.21533","article-title":"Pathophysiological concepts of restless legs syndrome","volume":"22","author":"Paulus","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archpsyc.64.3.327","article-title":"The Role of Dopamine in the Pathophysiology of Depression","volume":"64","author":"Dunlop","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/molecules23010040","article-title":"Dopamine and Levodopa Prodrugs for the Treatment of Parkinson\u2019s Disease","volume":"23","author":"Haddad","year":"2017","journal-title":"Molecules"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"113257","DOI":"10.1016\/j.jpba.2020.113257","article-title":"In vitro investigations on dopamine loaded Solid Lipid Nanoparticles","volume":"185","author":"Cometa","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2217\/nnm-2018-0417","article-title":"Improved brain delivery of pueraria flavones via intranasal administration of borneol-modified solid lipid nanoparticles","volume":"14","author":"Wang","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"27576","DOI":"10.3390\/ijms161126051","article-title":"Borneol Depresses P-Glycoprotein Function by a NF-\u03baB Signaling Mediated Mechanism in a Blood Brain Barrier in Vitro Model","volume":"16","author":"Fan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/bc.bc_13_18","article-title":"Effects of three flavonoids from an ancient traditional Chinese medicine Radix puerariae on geriatric diseases","volume":"4","author":"Zhang","year":"2018","journal-title":"Brain Circ."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2147\/IJN.S161237","article-title":"Enhanced permeability of blood-brain barrier and targeting function of brain via borneol-modified chemically solid lipid nanoparticle","volume":"13","author":"Song","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"150","DOI":"10.34172\/apb.2020.021","article-title":"Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery","volume":"10","author":"Chauhan","year":"2020","journal-title":"Adv. Pharm. Bull."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv. Pharm. Bull."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: Side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/03639045.2019.1593439","article-title":"Formulation and optimization of pioglitazone intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer\u2019s disease using Box-Behnken design","volume":"45","author":"Jojo","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3233\/JAD-160355","article-title":"Development of Nasal Lipid Nanocarriers Containing Curcumin for Brain Targeting","volume":"59","author":"Vaz","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s13346-018-0540-6","article-title":"In situ nanostructured hydrogel of resveratrol for brain targeting: In vitro-in vivo characterization","volume":"8","author":"Rajput","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12553-019-00380-x","article-title":"Nanocomposites: A brief review","volume":"10","author":"Hajlovac","year":"2020","journal-title":"Health Technol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-chembioeng-073009-100847","article-title":"Polymers for drug delivery systems","volume":"1","author":"Liechty","year":"2010","journal-title":"Ann. Rev. Chem. Biomol. Eng."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Ambrosio, L. (2010). The mechanics of biocomposites. Biomedical Composites, CRC Press. [1st ed.].","DOI":"10.1533\/9781845697372"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03639040903170750","article-title":"The application of mucoadhesive polymers in nasal drug delivery","volume":"36","author":"Jiang","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pneurobio.2008.09.009","article-title":"Nanotechnology, nanotoxicology, and neuroscience","volume":"87","author":"Suh","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"732954","DOI":"10.3389\/fphar.2021.732954","article-title":"Nano-in-Micro-Particles Consisting of PLGA Nanoparticles Embedded in Chitosan Microparticles via spray-Drying Enhances Their Uptake in the Olfactory Mucosa","volume":"12","author":"Spindler","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"121658","DOI":"10.1016\/j.ijpharm.2022.121658","article-title":"Particulate levodopa delivery targets dopamine to the brain without plasma exposure","volume":"618","author":"Dimiou","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","article-title":"Levodopa in Parkinson\u2019s Disease: Current Status and Future Developments","volume":"16","author":"Tambasco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"120827","DOI":"10.1016\/j.ijpharm.2021.120827","article-title":"Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation","volume":"605","author":"Manniello","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/1061186X.2019.1574300","article-title":"Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer\u2019s disease","volume":"27","author":"Manniello","year":"2019","journal-title":"J. Drug Target"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1706\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:50:39Z","timestamp":1760140239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":111,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071706"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071706","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}